Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in a...
EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without am...
Terumo Neuro announced that it has signed an agreement to acquire Arsenal Medical Inc., a privately held, clinical-stage biomaterials company developing Ne...
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronch...
InSilicoTrials, a cloud-based platform for AI and computational modeling and simulation in healthcare, today announced that it is a subawardee on a team ...
Marsico Pancreatic Cancer Initiative at CU Anschutz expands across institutions, pairing single-cell and spatial profiles with longitudinal outcomes fr...
– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS® System to Firefly’s nationwide network of Evoke™ cl...
Astellas Pharma Inc.announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, investigational KRAS G12D-t...
Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life scien...
Johnson & Johnson, a worldwide leader in multiple myeloma, announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment...
Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), reported interim results from a clinical st...
IntraBio Inc., a leader in the discovery, development, and commercialization of novel therapies for rare and common neurodegenerative diseases, announced...
Cue Biopharma, a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, announced positive topli...
© 2026 Biopharma Boardroom. All Rights Reserved.
